盐酸美金刚与盐酸多奈哌齐治疗阿尔茨海默病疗效对比

Efficacy comparison of memantine and donepezil in the treatment of Alzheimer's disease

目的比较盐酸美金刚与盐酸多奈哌齐治疗阿尔茨海默病(AD)的有效性和安全性。方法将72例AD患者随机分为2组:美金刚组36例给予盐酸美金刚片20mg/d,多奈哌齐组36例给予盐酸多奈哌齐10mg/d,2组疗程均为6个月。2组患者治疗前和治疗3个月、6个月后均采用简易智能精神状态检查量表(MMSE)和AD评定量表的认知次级量表(ADAS-cog)评价患者认知功能、精神行为及痴呆严重程度。结果经治疗3个月、6个月后,2组患者MMSE、ADAS-cog评分均较治疗前明显好转(P<0.05或P<0.01);治疗3个月、6个月后,2组患者MMSE、ADAS-cog评分比较差异无统计学意义(均P>0.05);美金刚组的不良反应发生率低于多奈哌齐组(χ2=4.5714,P>0.05)。结论盐酸美金刚与盐酸多奈哌齐均能显著改善AD患者的认知功能、日常生活能力和人格情感障碍,两药疗效无明显差异,且盐酸美金刚具有良好的安全性。

Objective Objective To compare the efficacy and safety of memantine and donepezil in the treatment of Alzhei- mefs disease. Methods Totally 72 cases of Alzheimer＇s disease were randomly classified into two groups： the memantine group（36 cases） was treated with memantine 20 mg/d, and the donepezil group （36 cases） was treated with 10 mg/d. The two groups were treated for 6 months. Mini mental state examination（MMSE） and Alzheimer＇s disease assessment scale cognitive subscale （ADAS cog） were used to evaluate patient＇s cognitive function, mental behavior and dementia severity before and after the treatment of 3 months, 6 months. Results The scores of MMSE and Adecco assessment scale after treatment of 3 months,6 months were all better than those before treatment in two groups（P〈0. 05 or P〈0.01 ） and there was no significant difference between the two groups after the treatment of 3 months, 6 months（all P〈0.05）. The adverse reaction rate of memantine group was lower than the donepezil group（X^2=4.57, P〉 0.05）. Conclusion As a safe and effective medicine, akatinol memantine, which has a similar effect as donepezil for AD, can remarkably improve the cognition, behavior, and mood of AD patients.